Jubilant Ingrevia (JUBLINGREA) Aktienübersicht
Jubilant Ingrevia Limited ist im Bereich biowissenschaftlicher Produkte und Lösungen in Indien, den Vereinigten Staaten, Europa, China und international tätig. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 1/6 |
| Künftiges Wachstum | 4/6 |
| Vergangene Leistung | 3/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 3/6 |
Belohnungen
Risikoanalyse
Bei unseren Risikoprüfungen wurden keine Risiken für JUBLINGREA festgestellt.
JUBLINGREA Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Jubilant Ingrevia Limited Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | ₹740.25 |
| 52-Wochen-Hoch | ₹795.00 |
| 52-Wochen-Tief | ₹537.30 |
| Beta | 0.28 |
| 1 Monat Veränderung | 2.49% |
| 3 Monate Veränderung | 3.95% |
| 1 Jahr Veränderung | 6.26% |
| 3 Jahre Veränderung | 75.87% |
| 5 Jahre Veränderung | -1.14% |
| Veränderung seit IPO | 175.49% |
Aktuelle Nachrichten und Updates
Analyseartikel • Jul 27
The Jubilant Ingrevia Limited (NSE:JUBLINGREA) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) last week reported its latest first-quarter results, which makes it a good...
Narrative-Update • Jul 13
JUBLINGREA: Upcoming Board Decisions May Temper But Sustain Current Optimism
Analysts have raised their price target on Jubilant Ingrevia from ₹657 to ₹705, citing revised assumptions on revenue growth, profit margins, and a lower future P/E multiple in their updated models. What’s in the News for Jubilant Ingrevia Jubilant Ingrevia has scheduled a board meeting on May 26, 2026, at 11:10 Indian Standard Time to review the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Recent updates
Analyseartikel • Jul 27
The Jubilant Ingrevia Limited (NSE:JUBLINGREA) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) last week reported its latest first-quarter results, which makes it a good...Narrative-Update • Jul 13
JUBLINGREA: Upcoming Board Decisions May Temper But Sustain Current Optimism
Analysts have raised their price target on Jubilant Ingrevia from ₹657 to ₹705, citing revised assumptions on revenue growth, profit margins, and a lower future P/E multiple in their updated models. What’s in the News for Jubilant Ingrevia Jubilant Ingrevia has scheduled a board meeting on May 26, 2026, at 11:10 Indian Standard Time to review the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Narrative-Update • Jun 15
JUBLINGREA: Upcoming Board Meeting And Dividend Decision Will Support Long Term Earnings Visibility
Analysts keep the Jubilant Ingrevia price target steady at ₹1,150, citing only marginal updates to the discount rate, revenue growth, profit margin, and future P/E assumptions that are not large enough to shift their overall view. What's in the News A board meeting is scheduled for May 26, 2026, at 11:10 a.m. IST to review the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Narrative-Update • Jun 01
JUBLINGREA: Upcoming Board Decisions Will Support Confidence In Long Term Earnings Visibility
Analysts have lifted their price target on Jubilant Ingrevia from ₹1,100 to ₹1,150 as they now apply a higher future P/E multiple, along with slightly lower assumptions for the discount rate, revenue growth and profit margin. What's in the News A board meeting is scheduled for May 26, 2026, at 11:10 IST to review audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).Narrative-Update • May 06
JUBLINGREA: Upcoming Meetings Will Highlight Risks To Current Optimism
Analysts have kept their price target for Jubilant Ingrevia steady at ₹657. Updated assumptions reflect slightly different views on discount rate, revenue growth, profit margin and future P/E to support this unchanged valuation.Narrative-Update • Apr 21
JUBLINGREA: Upcoming Postal Ballot Will Support Confidence In Long Term Earnings Visibility
Analysts keep the fair value estimate for Jubilant Ingrevia steady at ₹1,100, with only small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions guiding this unchanged price target. What's in the News Jubilant Ingrevia has scheduled a Special or Extraordinary Shareholders Meeting for April 4, 2026, to be conducted via postal ballot in India (Key Developments).Narrative-Update • Apr 07
JUBLINGREA: Upcoming Meetings Will Strengthen Confidence In Long Term Earnings Visibility
Analysts have kept the Jubilant Ingrevia price target unchanged at ₹1,100, with slight tweaks to model inputs such as discount rate, revenue growth, profit margin and future P/E, which underpin the refreshed view. What's in the News Board meeting scheduled for Feb 04, 2026 to consider unaudited standalone and consolidated financial results for the quarter ended Dec 31, 2025, which could provide fresh visibility on recent operating trends (Key Developments).Narrative-Update • Mar 24
JUBLINGREA: Upcoming Board Meeting Will Clarify Bullish Medium Term Outlook
Analysts have maintained the fair value for Jubilant Ingrevia at ₹657. A slightly lower discount rate, marginally higher assumptions for revenue growth and profit margins, and a modestly reduced future P/E expectation together shape the updated price target view.Narrative-Update • Mar 09
JUBLINGREA: Future Board Decisions Will Support Stronger Long Term Earnings Visibility
Analysts have trimmed their price target on Jubilant Ingrevia from ₹1,250 to ₹1,100. This reflects updated assumptions in their models around slightly softer revenue growth, lower profit margins and a higher future P/E multiple.Narrative-Update • Feb 23
JUBLINGREA: Upcoming Results And Refined Assumptions Will Shape Medium Term Outlook
Analysts have kept their fair value estimate for Jubilant Ingrevia unchanged at ₹657, while slightly adjusting their assumptions around discount rate, revenue growth, profit margin and future P/E to reflect a more balanced risk and earnings profile. What's in the News Board meeting scheduled on February 4, 2026, to consider the unaudited standalone financial results for the quarter ended December 31, 2025 (company filing).Narrative-Update • Feb 09
JUBLINGREA: Upcoming Results And Assumption Tweaks Will Shape Medium Term Outlook
Narrative Update The analyst price target for Jubilant Ingrevia has been revised from ₹695 to ₹657 as analysts factor in updated assumptions around the discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News Board meeting scheduled for Feb 04, 2026 to consider Unaudited Standalone Financial Results for the quarter ended Dec 31, 2025 (company filing).Analyseartikel • Feb 07
Earnings Miss: Jubilant Ingrevia Limited Missed EPS By 17% And Analysts Are Revising Their Forecasts
Shareholders might have noticed that Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) filed its quarterly result this time...Analyseartikel • Feb 04
Investors Still Waiting For A Pull Back In Jubilant Ingrevia Limited (NSE:JUBLINGREA)
Jubilant Ingrevia Limited's ( NSE:JUBLINGREA ) price-to-earnings (or "P/E") ratio of 36.6x might make it look like a...Narrative-Update • Jan 25
JUBLINGREA: Upcoming Board Review And Steady Margins Will Shape Medium Term Outlook
Analysts have maintained their fair value estimate for Jubilant Ingrevia at ₹695.00, making only minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions. This reflects a largely unchanged view on the stock's potential.Narrative-Update • Jan 10
JUBLINGREA: Upcoming Board Review And Margins Will Shape Medium Term Outlook
Analysts have kept their price target for Jubilant Ingrevia steady at ₹695. This reflects only marginal tweaks to assumptions on discount rate, revenue growth, profit margins and expected future P/E rather than a material shift in their overall view.Analyseartikel • Jan 06
These 4 Measures Indicate That Jubilant Ingrevia (NSE:JUBLINGREA) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Narrative-Update • Dec 26
JUBLINGREA: Upcoming Results And Margins Will Shape Balanced Medium Term Outlook
Analysts have made a modest upward revision to their price target for Jubilant Ingrevia to ₹695.00, reflecting slightly higher long term valuation multiples despite marginal trims to revenue growth and profit margin assumptions. What's in the News Board meeting scheduled for October 27, 2025, at 13:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing) Valuation Changes Fair Value: Unchanged at ₹695.00 per share.Narrative-Update • Dec 12
JUBLINGREA: Medium Term Margins And Growth Will Shape Fair Outlook
Analysts have reduced their price target for Jubilant Ingrevia to ₹695 from ₹743, reflecting more conservative assumptions on medium-term revenue growth and profit margins, despite a slightly lower discount rate and higher expected future valuation multiples. What's in the News Board meeting scheduled for October 27, 2025, at 13:30 IST to review the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).
Narrative-Update • Nov 27
JUBLINGREA: Solid Revenue Outlook And Profitable Operations Will Boost Future Upside
Analysts have maintained their price target for Jubilant Ingrevia at ₹987.75, citing stable revenue growth prospects and a largely unchanged outlook on profitability and valuation metrics. What's in the News A board meeting is scheduled for October 27, 2025 at 1:30 PM IST to consider the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).Narrative-Update • Nov 13
JUBLINGREA: Strong Profit Margins And Business Outlook Will Drive Share Upside
Analysts have slightly lowered their price target for Jubilant Ingrevia from ₹999.75 to ₹987.75. This change is based on minor adjustments in their valuation models, reflecting updated growth and profitability assumptions.Analyseartikel • Nov 07
Jubilant Ingrevia (NSE:JUBLINGREA) Shareholders Will Want The ROCE Trajectory To Continue
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...Narrative-Update • Oct 28
Improved Margins And Board Meeting Will Shape Export Opportunity Outlook
The analyst price target for Jubilant Ingrevia has been raised from ₹944.75 to ₹999.75. This reflects an improved margin outlook and a modestly higher profit forecast, according to analysts.Analyseartikel • Oct 17
Are Investors Undervaluing Jubilant Ingrevia Limited (NSE:JUBLINGREA) By 38%?
Key Insights The projected fair value for Jubilant Ingrevia is ₹1,143 based on 2 Stage Free Cash Flow to Equity...Analyseartikel • Sep 20
The Price Is Right For Jubilant Ingrevia Limited (NSE:JUBLINGREA)
With a price-to-earnings (or "P/E") ratio of 38.4x Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) may be sending bearish...Analyseartikel • Jul 03
We Like These Underlying Return On Capital Trends At Jubilant Ingrevia (NSE:JUBLINGREA)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...Analyseartikel • May 16
Jubilant Ingrevia Limited (NSE:JUBLINGREA) Analysts Are Pretty Bullish On The Stock After Recent Results
Last week saw the newest yearly earnings release from Jubilant Ingrevia Limited ( NSE:JUBLINGREA ), an important...Analyseartikel • Apr 22
Jubilant Ingrevia Limited's (NSE:JUBLINGREA) Share Price Matching Investor Opinion
Jubilant Ingrevia Limited's ( NSE:JUBLINGREA ) price-to-earnings (or "P/E") ratio of 51.7x might make it look like a...
Neues Narrative • Feb 17
International Expansion And New Vitamin B3 Facility Will Boost Presence In High-Value Products
Specialty Chemicals and Nutrition & Health segments are poised for growth, boosting revenue and margins through high-margin chemicals and vitamin B3 production.Analyseartikel • Feb 01
Jubilant Ingrevia (NSE:JUBLINGREA) Is Due To Pay A Dividend Of ₹2.50
Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) will pay a dividend of ₹2.50 on the 26th of February. Based on this...Analyseartikel • Jan 31
Results: Jubilant Ingrevia Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) last week reported its latest quarterly results, which makes it a good...Analyseartikel • Dec 18
Is Jubilant Ingrevia (NSE:JUBLINGREA) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Sep 11
We Think Jubilant Ingrevia (NSE:JUBLINGREA) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analyseartikel • Aug 14
Jubilant Ingrevia (NSE:JUBLINGREA) Is Reinvesting At Lower Rates Of Return
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...Analyseartikel • Jul 19
Jubilant Ingrevia Limited Just Missed Earnings - But Analysts Have Updated Their Models
As you might know, Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) last week released its latest quarterly, and things did...Analyseartikel • Apr 13
Earnings Tell The Story For Jubilant Ingrevia Limited (NSE:JUBLINGREA) As Its Stock Soars 29%
Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) shares have had a really impressive month, gaining 29% after a shaky...Analyseartikel • Feb 02
Jubilant Ingrevia Limited Just Missed EPS By 13%: Here's What Analysts Think Will Happen Next
Last week, you might have seen that Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) released its quarterly result to the...Analyseartikel • Feb 01
A Look At The Fair Value Of Jubilant Ingrevia Limited (NSE:JUBLINGREA)
Key Insights Jubilant Ingrevia's estimated fair value is ₹545 based on 2 Stage Free Cash Flow to Equity With ₹438 share...Analyseartikel • Oct 19
Returns At Jubilant Ingrevia (NSE:JUBLINGREA) Are On The Way Up
What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...Aktionärsrenditen
| JUBLINGREA | IN Chemicals | IN Markt | |
|---|---|---|---|
| 7D | -2.3% | 1.7% | 1.3% |
| 1Y | 6.3% | 1.3% | 5.9% |
Rendite im Vergleich zur Industrie: JUBLINGREA übertraf die Branche Indian Chemicals , die im vergangenen Jahr eine Rendite von 1.3 erzielte.
Rendite vs. Markt: JUBLINGREA entspricht dem Indian Markt, der im vergangenen Jahr eine Rendite von 5.9 erzielte.
Preisvolatilität
| JUBLINGREA volatility | |
|---|---|
| JUBLINGREA Average Weekly Movement | 4.8% |
| Chemicals Industry Average Movement | 6.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.7% |
Stabiler Aktienkurs: JUBLINGREA hatte in den letzten 3 Monaten im Vergleich zum Indian -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: JUBLINGREADie wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2019 | 2,185 | Deepak Jain | jubilantingrevia.com |
Jubilant Ingrevia Limited ist in Indien, den Vereinigten Staaten, Europa, China und international im Bereich der biowissenschaftlichen Produkte und Lösungen tätig. Das Unternehmen ist in drei Segmenten tätig: Spezialchemikalien, Nutrition & Health Solutions und chemische Zwischenprodukte. Das Segment Spezialchemikalien bietet Biopyridine und -picoline, Feinchemikalien, Agrochemikalien, kundenspezifische Entwicklungs- und Herstellungsdienstleistungen sowie Lösungen zur mikrobiellen Kontrolle an.
Jubilant Ingrevia Limited's Grundlagenzusammenfassung
| JUBLINGREA grundlegende Statistiken | |
|---|---|
| Marktanteil | ₹116.75b |
| Gewinn(TTM) | ₹3.09b |
| Umsatz(TTM) | ₹46.50b |
37.8x
Kurs-Gewinn-Verhältnis 2.5x
Kurs-Umsatz-VerhältnisIst JUBLINGREA zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| JUBLINGREA Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | ₹46.50b |
| Kosten der Einnahmen | ₹28.60b |
| Bruttogewinn | ₹17.90b |
| Sonstige Ausgaben | ₹14.82b |
| Gewinn | ₹3.09b |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
Oct 27, 2026
| Gewinn per Aktie (EPS) | 19.57 |
| Bruttomarge | 38.50% |
| Nettogewinnspanne | 6.64% |
| Schulden/Eigenkapital-Verhältnis | 25.3% |
Wie hat sich JUBLINGREA auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
0.7%
Aktuelle Dividendenrendite28%
AusschüttungsquoteZahlt JUBLINGREA eine zuverlässige Dividende?
Siehe JUBLINGREA Dividendenhistorie und Benchmarks| Jubilant Ingrevia Dividendentermine | |
|---|---|
| Ex-Dividenden Datum | Jul 24 2026 |
| Datum der Dividendenzahlung | Sep 25 2026 |
| Tage bis Ex-Dividende | 17 days |
| Tage bis zum Datum der Dividendenzahlung | 46 days |
Zahlt JUBLINGREA eine zuverlässige Dividende?
Siehe JUBLINGREA Dividendenhistorie und BenchmarksUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/10 08:56 |
| Aktienkurs zum Tagesende | 2026/08/07 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Jubilant Ingrevia Limited wird von 12 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Nitesh Dhoot | Anand Rathi Shares and Stock Brokers Limited |
| null null | Asian Markets Securities Private Limited |